• Insilico Medicine Cayman Topco nominated ISM9077, a potential first-in-class Target Y inhibitor, as a preclinical candidate for ocular diseases.
• Preclinical studies showed efficacy in dry AMD, uveitis, dry eye; results outperformed current therapies in the company’s models.
• Safety readouts indicated a wide safety margin; retinal exposure ran 2 to 5.5 times plasma levels.
• Data supported both oral dosing and topical eye-drop delivery, backed by permeability and retinal tissue exposure.
• ISM9077 is the 32nd preclinical candidate nominated since 2021; 13 prior nominees have received IND approval or clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608052030PR_NEWS_USPR_____CN19788) on August 06, 2026, and is solely responsible for the information contained therein.